Please login to the form below

Not currently logged in
Email:
Password:

Exscientia

This page shows the latest Exscientia news and features for those working in and with pharma, biotech and healthcare.

Fujitsu begins two-year medical AI research project

Fujitsu begins two-year medical AI research project

Meanwhile, last year saw an uptick in life sciences interest in applying AI to drug research, with the likes of Scotland’s Exscientia scoring deals withand Sanofi, and Lundbeck signing up

Latest news

  • Evotec invests €15m in AI firm Exscientia Evotec invests €15m in AI firm Exscientia

    Evotec invests 15m in AI firm Exscientia. Funds will help the Scottish group accelerate growth. ... As per the investment, Evotec’s chief operating officer, Dr Mario Polywka, will join Exscientia’s board of directors. .

  • GSK signs up to apply AI to drug discovery GSK signs up to apply AI to drug discovery

    GSK signs up to apply AI to drug discovery. Will work with Exscientia on 10 small molecule targets. ... John Baldoni, senior vice president, platform science and technology at GSK, said: "Exscientia has built an excellent team with proven innovation in

  • Sanofi agrees €250m diabetes deal with AI firm Exscientia Sanofi agrees €250m diabetes deal with AI firm Exscientia

    Sanofi agrees 250m diabetes deal with AI firm Exscientia. The French pharma giant will pay royalties and contribute research funding. ... Scottish biotech and artificial intelligence specialist Exscientia has added another pharma collaborator to its

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics